RA
NAMS icon

Rosalind Advisors’s NewAmsterdam Pharma NAMS Stock Holding History

Rosalind Advisors’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,123
Closed -$168K – 47
2024
Q3 		$168K Hold
10,123
– – 0.11% 30
2024
Q2 		$194K Buy
+10,123
New +$203K 0.15% 37

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Rosalind Advisors's NAMS Position: Q4 2024 in Review

Rosalind Advisors sold out of NewAmsterdam Pharma (NAMS) in Q4 2024, closing a stake of 10,123 shares — an estimated $168K sold.

Rosalind Advisors first reported a position in NAMS in Q2 2024 and held it in 2 quarters. The position peaked at $194K in Q2 2024. 130 funds tracked by Wall St. Rank hold NAMS as of Q4 2024.

  • Rosalind Advisors reported no remaining NewAmsterdam Pharma position as of Q4 2024 after selling out during the quarter.
  • Rosalind Advisors sold 10,123 NewAmsterdam Pharma shares in Q4 2024, an estimated $168K.
  • Rosalind Advisors first reported a position in NewAmsterdam Pharma in Q2 2024 and held it in 2 quarters.
  • Rosalind Advisors's NewAmsterdam Pharma position peaked at $194K in Q2 2024.
  • 130 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q4 2024.

Based on Rosalind Advisors's 13F filing for Q4 2024, filed 11 Feb 2025.